Kiromic settles SEC disputes for nondisclosure of clinical hold

Kiromic Biopharma Inc. and two former senior officials recently settled with the U.S. SEC after charges were brought against them for failing to disclose U.S. FDA clinical holds on two cancer candidates. These holds occurred both before and after a crucial public offering in July 2021, where the company raised $40 million, funds they urgently needed.

This settlement highlights the importance of transparency in the biopharmaceutical industry, particularly when it comes to disclosing information that could impact investors. By addressing these charges, Kiromic Biopharma Inc. and its former officials are taking steps to ensure compliance with regulatory requirements and maintain trust within the industry.

For more updates on regulatory matters, cancer research, cell therapy advancements, and other industry news, be sure to subscribe to BioWorld™ news services for all the latest information. Stay informed and connected to the latest developments shaping the biopharma landscape.